Schering-Plough CEO Fred Hassan: An Interview With “The Pink Sheet” DAILY (Part 3 of 3)

 
• By Jonathan M. Block

Hassan discusses Schering’s late-stage pipeline, including the protease inhibitor boceprevir for hepatitis C and SCH 530348, a thrombin receptor agonist intended as an add-on to Plavix therapy.

More from Archive

More from Pink Sheet